It is known that 5-HT4 receptors in the colon of guinea pigs show a distribution similar to that in humans. Thus, we examined the effects of mosapride citrate (mosapride) and cisapride, two 5-HT4receptor agonists, on colonic motility in conscious guinea pigs implanted with force transducers. Mosapride and cisapride administered intragastrically at doses of 3 -30 mg /kg significantly enhanced the colonic motility. The enhancing effect of mosapride was antagonized by atropine or GR113808, a 5-HT 4 -receptor antagonist, but not by methysergide, a 5-HT 1 -and 5-HT 2 -receptor antagonist; ondansetron, a 5-HT 3 -receptor antagonist; or CP-99994, a tachykinin NK 1 -receptor antagonist. In vitro receptor autoradiography showed that mosapride and cisapride inhibit the specific binding of [ 125 I]-SB207710, a selective radioligand of 5-HT 4 receptors, in the colon of guinea pigs. These results suggest that mosapride enhances colonic motility through the 5-HT 4 -receptor activation in guinea pigs and may be useful for treating constipation in patients with colonic motility dysfunction.
5-Hydroxytryptamine (5-HT)
receptor is abundantly distributed along the gastrointestinal (GI) tract and modulates smooth muscle tone, peristaltic reflex and mucosal secretion (1, 2) . Especially, 5-HT 4 receptor modulates gastrointestinal motility by excitatory and /or inhibitory actions depending on animal species and anatomical regions (3) . For example, stimulation of 5-HT4 receptors enhances electrical field stimulation (EFS)-induced contractions in isolated human (4) and guinea pig stomach (5) and ileum (6) , but induces relaxation in isolated rat esophagus and ileum and human colon circular muscle (7) . In addition, in vivo studies have shown that stimulation of 5-HT4 receptors enhances gastric emptying in rats and gastrointestinal motility in dogs and humans (8 -11) .
Mosapride citrate (Mosapride), a selective and potent 5-HT4-receptor agonist, increases the gastric emptying in rats and human (8, 12) and alleviates gastrointestinal dysfunctions in patients with nonulcer dyspepsia and gastroesophageal reflux disease (12, 13) . However, the prokinetic effect of mosapride on GI motility was somewhat different from that of other 5-HT4-receptor agonists such as cisapride, renzapride and zacopride (9, 12, 14) . Specifically, mosapride selectively enhanced the motility of upper GI tract, such as in the stomach and duodenum, whereas cisapride and zacopride stimulated the motility in all sites of the GI tract from the stomach and the colon in conscious dogs (12, 14) . It has been recently reported that mosapride may be effective against constipation in patients with dysfunction of the lower GI motility (15) . From these findings, it is suggested that the mechanism of colonic motility enhancement is different between humans and dogs.
Recent studies, using in vitro receptor autoradiograms of the stomach and colon have shown that the distribution of 5-HT4 receptors in guinea pigs is similar to that in humans (16, 17) . In addition, Sakurai-Yamashita et al. (16) reported that 5-HT 4 receptors are present in the myenteric plexus and the muscle of both human and guinea pig colon. These results suggest that the effects of 5-HT4 receptor agonists on colonic motility in the guinea pig are similar to those in humans.
In the present study, we examined whether mosapride and cisapride, two 5-HT 4 -receptor agonists, affect colonic motility in conscious guinea pigs implanted with force transducers. In addition, using in vitro receptor autoradiography, we examined the effects of mosapride and cisapride on the specific binding of [ 125 I]SB207710, a 5-HT4-receptor radioligand, in the guinea pig colon.
MATERIALS AND METHODS

Animals
Male Hartley guinea pigs weighing 300 to 550 g were used. They were purchased from Shizuoka Laboratory Animal Center in Japan and housed in rooms with a 12-h light-dark cycle and controlled temperature (23 ± 2°C) and humidity (55 ± 15%) under free access to food (RC-4; Oriental Yeast Co., Ltd., Tokyo) and tap water.
Drugs
Mosapride, GR113808 ([1-[2-(methylsulphonylamino) ethyl]-4-piperidinyl]methyl-1-methyl-1H-indole-3-carboxylate), ondansetron hydrochloride and (±)-CP-99994 ((±)-3-(2-methoxybenzylamino)-2-phenylpiperidine) were synthesized in our Discovery Research Laboratories. The other compounds were purchased commercially: cisapride (extracted from Acenalin; Kyowa Hakko Kogyo Co., Ltd., Tokyo), atropine sulfate (Sigma Chemical Co., St. Louis, MO, USA), methysergide maleate (Sandoz Ltd., Basel, Switzerland), and [ 125 I]SB207710 (74 TBq /mmol, (1-nbutyl-4-piperidinyl)methyl-8-amino-7-iodo-1,4-benzodioxane-5-carboxylate; Amersham, Buckinghamshire, UK). The dose of each antagonist used was chosen because the dose had been reported in previous studies (8, 14, 18, 19) to be effective in antagonizing the listed receptors. In the in vivo study, mosapride, and cisapride were suspended in 0.5% tragacanth solution. GR113808 and methysergide maleate were dissolved in 0.5% (vol /vol) lactic acid and dimethylsulfoxide (DMSO), respectively. They were diluted to the required concentrations with distilled water. Atropine sulfate, ondansetron hydrochoride and CP-99994 were dissolved in saline. In the in vitro study, mosapride and GR1138308 were dissolved in DMSO, and cisapride was dissolved in ethanol. These were then diluted to the required concentrations with distilled water, and the final solvent concentration did not exceed 0.1% DMSO or 0.1% ethanol in the working buffer.
Motility in conscious guinea pigs
Animal preparation: Male Hartley guinea pigs were anesthetized with sodium pentobarbital (35 mg /kg, i.p.), and the abdomen was opened by midline laparatomy. A force transducer (F-08IS; Star Medical, Inc., Tokyo) was sutured on the serosal surface to record contractions of the circular muscles on the proximal colon 8-cm distal to the ileocecal junction. A polyethylene tube was then inserted into the gastric body for drug injection. In some animals, the tube was inserted into the jugular vein for intravenous injection of drugs in addition to the intragastric tube.
The lead wires of the transducer in the abdominal cavity were brought out through a skin incision made between the scapulae to the back skin, and the skin incision of the abdomen was closed. After the surgical operation, the guinea pig was put on a jacket with a connecter, and the outer lead wires were attached to a small connecter for protection. The animal was then housed in an individual cage until use.
Colonic motor activity was recorded by connecting the lead wires of the transducer to an amplifier (FS-04M, Star Medical, Inc.) which was in turn connected to a chart recorder (SR6221; Graphtec, Inc., Tokyo). At the same time, the amplified signals were continuously recorded on a computer (PC-9821 /BP; NEC, Inc., Tokyo) and analyzed by its own processing system. The motor index (MI) given by the processing system corresponded to the measurement of the area surrounded by the contraction wave and the base line; i.e., the product of the amplitude and the time in seconds during a certain fixed period.
Experimental procedure: Measurement of the motor activity was performed at least 2 days after the surgical operation. The animal was placed in a plastic cage with a wire-meshed bottom to avoid coprophagy during the experiment, and a test drug was administered intragastrically at the time between 14:00 pm and 15:00 pm through the cannulated tube.
Colonic motor activities were expressed as MI (%); i.e., the percentage of the mean motor index at 30-min interval for 60 min before administration of the vehicle or drug.
In antagonistic studies, atropine, GR113808, methysergide, ondansetron or CP-99994 was first administered intravenously and then by continuous intravenous infusion at a rate of 1 ml /h for 30 min starting 30 min after vehicle or drug intragastric administration. Colonic motor activities were expressed as MI (%), i.e., percentage of the mean colonic motor index at 30-min interval for 60 min before vehicle or drug administration.
Receptor autoradiography
Male Hartley guinea pigs were killed by cervical dislocation. The proximal colon was rapidly excised and the mucosa was removed by a cotton stick. The tissues were immediately frozen by carbon dioxide snow and cut into 20-mm-thick sections using a cryostat thaw-mounted onto gelatin-coated glass slides. They were then dried overnight under vacuum at 4°C and stored at -80°C until use. Following preincubation in 50 mM Tris-HCl buffer (pH 7.4) containing 4 mM MgCl2 and 0.3% bovine serum albumin for 30 min at room temperature, the tissue sections were incu-bated with 10 pM of [ 125 I]SB207710, a specific 5-HT 4receptor radioligand, in 50 mM Tris-HCl buffer (pH 7.4) containing 4 mM MgCl2, 10 mM pargyline, 0.3% bovine serum albumin and 0.2 mM ascorbic acid for 2 h at room temperature in the presence or absence of several concentrations of the drug. Non-specific binding was determined in the presence of 1 mM GR113808, a specific 5-HT 4receptor antagonist. The labeled sections were then washed three times (for 1 min each) at 4°C with 50 mM Tris-HCl buffer (pH 7.4), tapped in ice-cold distilled water, and dried under a stream of cold air. Radioligand binding sites were quantified using a computerized radioluminographic imaging-plate system (Bio-imaging analyzer BAS 2000; Fuji Photo Film Co., Tokyo) with calibrated [ 125 I] standards ([ 125 I]microscales; Amersham). To obtain autoradiograms of a higher resolution, the dry-labeled sections were apposed against Hyperfilm-[ 3 H] (Amersham) for 2 weeks, and then the films were developed using a D19 developer (Eastman Kodak, Rochester, NY, USA).
Statistical analyses
The results are represented as the mean ± S.E.M. Statistical analyses were performed using the SAS system (ver 6.12; SAS Institute Inc., Cary, NC, USA). Comparisons of MI (%) values between vehicle-and test drugtreated groups were analyzed by repeated measures twoway ANOVA (factors: time after drug administration and group). In case of a significant interaction between time and group, the significant difference in each period was analyzed by the Dunnett multiple comparison test. Comparisons of MI (%) values between vehicle-and test drugstreated groups in the presence of each antagonist were performed with the t-test. A level of P<0.05 was considered to be significant.
The IC50 value, i.e., the concentration required for 50% inhibition of specific [ 125 I]SB207710 binding, was determined by linear regression analysis (Probit method).
RESULTS
Colonic motility in untreated conscious guinea pigs
Typical tracings of proximal colonic motility in an untreated conscious guinea pig implanted with a force transducer are shown in Fig. 1 . Motility patterns are characterized by sporadic low (A) and high (B) amplitude contractions, sometimes superimposed by high amplitude and clustered contractions (C) lasting for approximately 10 min.
Effects of tragacanth, mosapride and cisapride on colonic motility in conscious guinea pigs
Treatment with 0.5% tragacanth solution (1 ml /kg, i.g.) as vehicle slightly affected colonic motility ( Fig. 2A) . The colonic MI (%) for each 30-min interval after vehicle administration slightly increased from 95.9 ± 7.3% to 100.6 ± 6.5%. Typical tracings of the effects of mosapride (10 mg /kg, i.g.) and cisapride (3 mg /kg, i.g.) on colonic motility are shown in Fig. 2 : B and C. Mosapride at doses of 3, 10 and 30 mg /kg, i.g. dose-relatedly increased the amplitude of colonic motility with MI (%) values of 128.2 ± 12.2% (P = 0.042), 147.3 ± 15.0% (P = 0.001) and 187.9 ± 19.5% (P = 0.000), respectively. However, at a dose of 1 mg /kg, i.g., mosapride had no effect on colonic motility in conscious guinea pigs (Fig. 3A) . Although cisapride at doses of 3 and 30 mg /kg, i.g. also significantly increased the amplitude of colonic motility with MI (%) values of 222.6 ± 33.3% (P = 0.011) and 242.0 ± 56.5% (P = 0.003), respectively, its effect at a dose of 0.3 mg /kg, i.g. was negligible (Fig. 3B ).
Antagonistic studies
Although atropine (0.1 mg /kg, i.v., followed thereafter with 0.1 mg/kg per hour, i.v. infusion) reduced the amplitude of colonic motility contractions, some atropine-resistant contractions were observed (Fig. 4A) . Moreover, the enhanced colonic motility induced by mosapride (10 mg /kg, (opened squares) and mosapride at 1 mg /kg, n = 6 (closed diamonds); 3 mg /kg, n = 6 (opened circles); 10 mg /kg, n = 6 (closed triangles); and 30 mg /kg, n = 6 (opened triangles). B: Vehicle, n = 18 (opened squares), cisapride 0.3 mg /kg, n = 6 (closed diamonds), 3 mg/kg, n = 6 (opened circles), 30 mg /kg, n = 6 (closed triangles). Colonic motor activities are expressed as the percentage of the control motor index. The control motor index, i.e., the mean of the motor index of each 30-min interval for 60 min before drug administration, is expressed as 100%. Drugs were administered intragastrically at time 0. Each point represents the mean ± S.E.M. n: number of animals. *P<0.05 and **P<0.01: statistically significant difference from the vehicle group (Dunnett's test).
i.g.) was antagonized by treatment with atropine ( Fig. 4B ).
GR113808, methysergide or CP-99994, first all given at a dose of 0.1 mg /kg, i.v. and thereafter by 1 mg /kg per hour, i.v. infusion for 30 min, slightly affected the basal colonic motility (Fig. 5 ). Ondansetron (0.5 mg /kg, i.v., followed thereafter with 0.5 mg /kg per hour, i.v. infusion for 30 min) slightly increased the basal colonic motility (Fig. 5) . Moreover, the enhancement of colonic motility induced by mosapride (10 mg /kg, i.g.) was almost completely inhibited by treatment with GR113808, but not by the treatment with ondansetron, methysergide, or CP-99994 (Fig. 5 ). The enhancement of colonic motility induced by cisapride (3 mg /kg, i.g.) was also completely inhibited by treatment with GR113808 (data not shown).
Receptor autoradiography
Specific binding of [ 125 I]SB207710 was detected in muscle layers and the myenteric plexus dissected from the proximal colon of the guinea pig and [ 125 I]SB207710 binding in the proximal colon was abolished in the presence of GR113808 (1 mM) (data not shown). The specific binding of 10 pM [ 125 I]SB207710 in the colon was 12. 
DISCUSSION
This is the first report showing the effects of drugs on colonic motility by using the force transducers in conscious guinea pigs, although in vitro studies using isolated preparations have been frequently performed to examine the pharmacological actions of drugs on guinea pig colon. To our knowledge, only a few studies have investigated the physiological and pharmacological characterization of GI motility in the stomach and small intestine in conscious guinea pigs (18) ; however, those of colonic motility have not been investigated. In the present study, we recorded colonic motility in conscious guinea pigs implanted with force transducers and examined the effects of 5-HT4-receptor agonists (mosapride and cisapride) on colonic motility. Our results show that the typical colonic motility pattern in untreated conscious guinea pigs is mainly characterized by sporadic low and high amplitude contractions, sometimes superimposed by clustered contractions lasting for approximately 10 min.
Mosapride and cisapride were found to enhance the amplitude of colonic motility in conscious guinea pigs. These results are clearly different from those showing that mosapride slightly affects colonic motility in conscious dogs implanted with force transducers, but are consistent with results showing that cisapride stimulates motor activity in all sites of the GI tract in conscious dogs (9, 14) . From the present study and our previous reports (9, 14) , it is therefore suggested that there are differences between the effects of mosapride on colonic motility in guinea pigs and in dogs. In this aspect, further experiments are necessary to clarify the differences.
The enhancement of colonic motility induced by mosapide in conscious guinea pigs was antagonized by treatment with atropine or GR113808, a selective 5-HT 4 -receptor antagonist (20, 21) . In contrast, the enhancing effect of mosapride on colonic motility was not prevented by treatment with methysergide, a non-selective 5-HT 1 -and 5-HT2-receptor antagonist or ondansetron, a selective 5-HT3receptor antagonist. Recently, it has been reported that in isolated guinea pig proximal colon, the contractions caused by stimulation of 5-HT4 receptors are mediated by a cholinergic neurotransmitter and tachykinin NK1-stimulating neurotransmitters such as substance P and neurokinin A (22) . In the present study, it was found that the enhancement of colonic motility induced by mosapride was not prevented by CP-99994, a tachykinin NK1-receptor antagonist, in conscious guinea pigs. These results suggest that tachykinin NK1 receptors are not involved in the enhancing effect of mosapride on colonic motility in conscious guinea pigs. From these findings, it has been indicated that mosapride enhances colonic motility by stimulation of the 5-HT4 receptor that increases acetylcholine release from nerve endings in conscious guinea pigs. Recently, it has been reported that the 5-HT 4 receptors is involved in the 5-HT release from intestinal enterochromaffin cells (23, 24) . For example, Minami et al. reported that a selective 5-HT 4 -receptor agonist, 5-methoxytryptamine induces a concentration-dependent increase of 5-HT release in rat ileum (23) . From these evidence, it may be possible that mosapride enhances GI motility by the stimulation of 5-HT release as well as acetylcholine release from the GI tract.
Although the distribution of 5-HT4 receptors has been recently established in the colon of guinea pigs (16, 17) , there are no reports showing that 5-HT4-receptor agonists bind to colonic 5-HT4 receptor sites. Thus, in order to confirm the in vivo effects of mosapride and cisapride, we performed in vitro receptor autoradiography using [ 125 I]SB207710, a specific 5-HT4-receptor ligand (25) . The specific binding sites of [ 125 I]SB207710 were detected in muscle layers and the myenteric plexus dissected from the proximal colon in guinea pigs. Treatment with GR113808 abolished the binding of [ 125 I]SB207710, indicating that 5-HT 4 receptors are present in the colon. These results are consistent with those reported by Sakurai-Yamashita et al. (16) . Mosapride and cisapride were found to inhibit the specific 5-HT 4 receptor binding of [ 125 I]SB207710 in the colon as in case of GR113808. From these in vitro and in vivo experiments, it is believed that the enhancing effects of mosapride and cisapride on colonic motility are mainly mediated via stimulation of 5-HT4 receptors located in the colon of the guinea pig.
Recently, selective 5-HT 4 -receptor agonists such as prucalopride and tegaserod, have been demonstrated to facilitate colonic transit and increase stool frequency, and they have been proven valuable for the treatment of slow transit constipation (26) . From these findings and the fact that the distribution of 5-HT4 receptors in the colon of guinea pigs is similar to that in the colon of humans (16, 17) , it is suggested that mosapride enhances colonic motility through 5-HT4-receptor activation in guinea pigs and that this enhancement of colonic motility as well as gastric motility may lead to improvement of constipation in patients with dysfunction of the lower GI motility.
In conclusion, mosapride and cisapride showed enhancing effects on colonic motility in conscious guinea pigs. Accordingly, it is suggested that the measurement of colonic motility in conscious guinea pigs implanted with force transducers is useful for detecting the whole effects of 5-HT4-receptor agonists or antagonists on the colonic motility and for predicting their efficacy in humans. 
